NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
Clinical Trials
8 trialsNCT04753203 2023-10-31
ALCAP
Korean Cancer Study Group
Phase 1/2 Unknown
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT04526470 2021-08-24
Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer
Seoul National University Bundang Hospital
Phase 1/2 Unknown
NCT02155088 2021-04-08
BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02550743 2021-03-12
BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study
Brown University
Phase 1 Terminated
NCT01822613 2020-12-19
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
Novartis
Phase 1 Completed
NCT01613950 2020-12-09
PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer
Novartis
Phase 1 Completed